Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market is expected to reach US$ 64.09 Billion by 2033 | Emerging key players - Arrowhead Pharmaceuticals Inc., Intellia Therapeutics, Inc.

Market Size and Growth:

The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market size reached US$ 4.32 Billion in 2024 and is expected to reach US$ 64.09 Billion by 2033, growing at a CAGR of 35.3% during the forecast period 2025-2033.

Transthyretin Amyloid Cardiomyopathy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market?sz

The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market encompasses the diagnosis, treatment, and management of a rare, progressive heart condition caused by transthyretin protein deposits in the heart. It includes pharmacological therapies, supportive care, and emerging treatments aimed at slowing disease progression, improving cardiac function, and enhancing patients' quality of life, driven by rising awareness and advancements in precision medicine.

Industry News of USA and Japan:

USA

March 2025: The U.S. FDA approved AMVUTTRA (vutrisiran) for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This is the first gene-silencing therapy approved for ATTR-CM.

November 2024 (mentioned in 2025 reports): Acoramidis (Attruby) was approved by the FDA, becoming the second TTR stabilizer approved for ATTR-CM.

Japan

March 2025: The Japanese Ministry of Health, Labour and Welfare approved acoramidis, under the brand name Beyonttra, for the treatment of adults with ATTR-CM.

March 2025: The approval was based on positive results from a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial.

Key Players:

Pfizer Inc.

Emerging Players:

Arrowhead Pharmaceuticals Inc.
Intellia Therapeutics, Inc.

Growth Forecast Projected:

The Global Transthyretin Amyloid Cardiomyopathy Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Transthyretin Amyloid Cardiomyopathy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=transthyretin-amyloid-cardiomyopathy-market

Market Segmentation:

By Type: Familial (hereditary) ATTR-CM, Wild-type ATTR-CM.

By Drug Type: Transthyretin Stabilizers, RNAi Therapy, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/transthyretin-amyloid-cardiomyopathy-market

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Transthyretin Amyloid Cardiomyopathy market?

➠ Who are the leading manufacturers in the global Transthyretin Amyloid Cardiomyopathy industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Transthyretin Amyloid Cardiomyopathy industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Transthyretin Amyloid Cardiomyopathy market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.